The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors
Abstract Therapy of melanoma has improved dramatically over the last years thanks to the development of targeted therapies (MAPKi) and immunotherapies. However, drug resistance continues to limit the efficacy of these therapies. Our research group has provided robust evidence as to the involvement o...
| 發表在: | Cell Death and Disease |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Nature Publishing Group
2024-03-01
|
| 在線閱讀: | https://doi.org/10.1038/s41419-024-06580-2 |
